Genetic discoveries in AD using CSF amyloid and tau

Area of Science:

• Neuroscience
• Genetics
• Biomarkers

Background:

• Alzheimer's disease (AD) genetic studies utilize cerebrospinal fluid (CSF) biomarkers Aβ42 and pTau181.
• These endophenotypes have successfully identified rare and common AD risk variants.
• This approach generates hypotheses for how AD risk variants influence disease mechanisms.

Purpose of the Study:

• To discuss the successes of using CSF biomarkers in AD genetic studies.
• To outline challenges and propose solutions for effective application of this approach.
• To explore future directions including larger sample sizes and next-generation sequencing.

Main Methods:

• Analysis of CSF Aβ42 and pTau181 levels as endophenotypes.
• Comparison of statistical power with traditional case-control designs.
• Discussion of quality control and data analysis strategies.

Main Results:

• Successful identification of AD risk variants using CSF biomarkers.
• Generation of biological hypotheses for variant effects.
• Demonstration of the utility of this approach in advancing AD research.

Conclusions:

• CSF biomarkers are powerful tools for AD genetic research.
• Addressing challenges in data quality and analysis is crucial for continued success.
• Future applications with larger cohorts and advanced sequencing hold significant promise for AD research.